CD4 cell counts at the third month of HAART may predict clinical failure

AIDS

Volumn 13, Issue 13, 1999, Pages 1669-1676

  D'Arminio Monforte, Antonella ^a,c   Testori, Valeria ^a   Adorni, Fulvio ^b   Castelnuovo, Barbara ^a   Bini, Teresa ^a   Testa, Letizia ^a   Moscatelli, GianCarla ^a   Chiesa, Elisabetta ^a   Rusconi, Stefano ^a   Abeli, Clara ^a   Sollima, Salvatore ^a   Musicco, Massimo ^b   Meroni, Luca ^a   Galli, Massimo ^a   Moroni, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

3 month CD4 cell count; Clinical failure; Highly active antiretroviral therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ARTICLE; DEATH; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REGRESSION ANALYSIS; STATISTICS; TREATMENT FAILURE; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 16744365520     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00010     Document Type: Article

References (25)

1. Cameron DW, Hearth-Chiozzi M, Danner S et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
2. Hammer SM, Kathleen ES, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. Clumeck N on behalf of the Saquinavir International Phase III Trial (SV 14604) Group. Clinical benefit of Saquinavir (SQV) plus Zalcitabine (ddC) plus Zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997 [abstract LB-4].
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus Syndrome. N Engl J Mod 1998, 338:853-860.
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997, 11:F101-F105.
6. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
7. Schneider MME, Borleffs JCC, Stolk RP, Japers CAJJ. Hoepelman IM. Discontinuation of Pneumocystits carinii pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 1999, 353:201-203.
8. Fatkenheuer G, Theisen A, Roskstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
9. d'Arminio Monforte A, Testa L, Adorni F et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998, 12:1631-1637.
10. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy, JAMA 1996, 276:1955-1956.
11. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.
12. US Department of Health and Human Services, Public: Health Service, Centers for Disease Control and Prevention (CDC), 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. MMWR 1997, 46:RR-12.
13. 1993 Revised Classification System for HIV infection and Expanded Surveillance Case Definition for AIDS among adolescents and adults. MMWR 1992, 41:19-23
14. Chene G, Binquet C, Moreau J-F, et al. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. AIDS 1998, 12:2313-2320.
15. Michelet C, Arvieux C, François C, et al. Opportunistic infections occurring during highly active antiretroviral treatment, AIDS 1998, 12:1815-1822.
16. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998, 280:72-77.
17. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. lancet 1997, 349:1443-1445.
18. Tural C, Romeu J, Andreu D, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998, 177:1080-1083.
19. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RR. and the Zidovudine Epidemiology Study Group. incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992, 166:1223-1227.
20. d'Arminio Monforte A, Mainini F, Testa L, et al. Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. AIDS 1997, 11:517-524.
21. d'Arminio Monforte A, Vago L, Gori A, et al. Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS. Eur J Clin Microbiol Infect Dis 1996, 15:453-458
22. Meroni L, Varchetta S, Manganaro D, Moscatelli CC, Moroni M, Galli M. CD4+CD7-lymphocyte subset is expanded in HIV infected patients with low CD4+ cell count rescue during HAART. AIDS 1999, in press.
23. Levy JA. Caution: should we be treating HIV injection early? Lancet 1998, 352:982-983.
24. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 31-February 4, 1999 [abstract n 98].
25. Ridolfo AL, Mainini F, Santambrogio S, et al. AIDS features in patients unaware of their HIV-seropositivity. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 22-26 January, 1997, [abstract 503].